Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Ketamine to become Class B drug
Ketamine
New evidence suggests frequent, high doses of ketamine cause chronic toxicity.
Serious harm caused by misuse, latest review warns

Ketamine is to be become a Class B drug after a report recently highlighted growing evidence of serious physical and psychological harm where the drug is heavily and frequently misused.

Minister for crime prevention Norman Baker confirmed the move following a review by the Advisory Council on the Misuse of Drugs (ACMD).

In its first review of the drug since 2004, the council also recommended ketamine be placed in Schedule II of the Misuse of Drugs Regulations 2001.

Ketamine is widely used in veterinary medicine as an anaesthetic and analgesic, as well as some areas of human medicine.

According to the ACMD, 120,000 individuals are estimated to have misused ketamine in 2012 to 2013.

The council's latest report details new evidence of chronic toxicity to the bladder resulting in numerous reports of individuals having to have their bladders removed.

In addition to this, for regular high-dose users the drug is believed to cause a range of psychological and physical problems, as well as significant toxicity to the urinary tract and kidneys.

In a letter to ACMD, Mr Baker said: "I accept your recommendation to reclassify ketamine as a Class B drug. I have taken this decision in light of the evidence of chronic harms associated with ketamine use, including chronic bladder and other urinary tract damage highlighted in the Advisory Council's report."

Mr Baker added that parliamentary proceedings to reclassify the drug will begin shortly. A consultation will be held on the rescheduling of ketamine in order to determine the effect this will have on veterinary and healthcare sectors.

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.